Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023
In 2023, Cosmos Health concluded multiple acquisitions, including Cana Laboratories, the distribution network owned by Bikas GP, and ZipDoctor.These acquisitions...
Pharmaceutical
BioHarvest Sciences Inc. Closes Final Tranche of Oversubscribed $13.5M Private Placement
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 27, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV)...
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median...
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec....
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα...
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts...
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups...
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240...
Algernon Pharmaceuticals Announces Increase to Private Placement
VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class...
Opthea to Receive US$35M Commitment and Additional US$50M Funding
Opthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth,...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and...
TLC to Present at the 42nd Annual JP Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 27, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty...
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
ORION CORPORATION PRESS RELEASE 27 DECEMBER 2023 at 11:00 EET NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208...
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
NORTHVALE, NJ / ACCESSWIRE / December 26, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical...
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
$5 million at closing and up to $7 million of additional committed fundingSAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --...
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
Proceeds expected to extend cash runway into H2 2027VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq:...
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment...
Harpoon Therapeutics Strengthens Leadership Team
James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec....
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading...